Takeda announced the launch of an Access to Medicines (AtM) strategy aimed at increasing access to its innovative and potentially life-saving medicines.
Med Ad News interviewed Josh Prince, CEO of DDB Health, CMO of Omnicom Health Group and Jury President of Health & Wellness Lions 2016.
There is no place more social than Cannes. (Just spend an evening at The Gutter Bar.) And, yet, when it comes to creative ideas using social media, social didn’t really show up on the pharma shortlist this year.
Healthcare promotion strikes me as a cozy little business sometimes, with our webs of contacts and clients, strongly strung in a specialized space. Nowhere did I feel this more than at Cannes, where Lions Health, in its own building at the Palais, gave us a chance to renew friendships and make new contacts easily, fueled by the appropriately sized venue and the gallons of pink wine.
Recurring themes explored at Lions Health this year included empathy. The term was tossed around in all sorts of contexts – health bias, gaps in care, disease stigma, aging. For the most part, it was centered on better understanding between the health industry and people in health crisis. For me, as a creative leader and armchair strategist, empathy is most powerful in connecting ideas to audiences.
Life changing creativity is what the Cannes Lions Festival is all about. It is wonderful to see the health and wellness industry getting engaged in creating and celebrating creativity and innovation on a global stage.
It’s no secret that marketing has grown in complexity in the last few decades, coupled with the rise in digital technologies. Unless you’ve been completely disconnected, you likely know that the newest phenomenon in this world is Pokémon Go, an app-based game that has single-handedly taken over the technological world.
Gilead Sciences Inc. announced that two Phase 3b switch studies evaluating Odefsey (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for the treatment of HIV-1 infection met their primary objectives.
Merck said the U.S. Food and Drug Administration has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application for bezlotoxumab, an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence.
Medivation Inc. sent a letter to stockholders providing detailed information to correct the misleading claims Sanofi has made as part of its coercive efforts to acquire Medivation at an opportunistic, low price that substantially undervalues Medivation.
